A high expression of C5orf58 in patients with melanoma in different datasets (34, 37) indicated worse response to anti-PD-1/anti-CTLA-4 combined therapy, leading to worse overall survival or progression-free survival (Figures 8A, D, E). The gene discussed is CTLA4; the disease is melanoma.